Literature DB >> 28739209

Analytical and biological variation in repeated sweat chloride concentrations in clinical trials for CFTR modulator therapy.

V A LeGrys1, T C Moon2, J Laux3, M J Rock4, F Accurso5.   

Abstract

BACKGROUND: Using sweat chloride as a biomarker for CFTR modifying drugs requires knowledge of analytical and biological variation.
METHODS: 979 sweat chloride concentrations from 128 subjects enrolled in the placebo arm of 2 multicenter, investigational drug trials were analyzed to determine coefficients of variation (CV) as well as reference change value (RCV) and index of individuality (II).
RESULTS: For these populations, calculated values for the two studies were: analytical variation (3.9, 4.1%); within-subject variation (4.4, 6.0%); between-subject variation (8.9, 7.0%); RCV (13.7, 17.0%) and II (0.7, 1.0). Sweat chloride variation was not affected by sex, collection site or sample weight; but was slightly affected by age in one of the two studies.
CONCLUSION: Through determination of analytical as well as between- and within-subject variation, and with a larger sample size, our data allows improved estimates of the RCV and II, and can contribute to future trials of CFTR modulators and inform the design and interpretation of n of 1 trials in both research and clinical settings.
Copyright © 2017 European Cystic Fibrosis Society. Published by Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Analytical variation; Biological variation; Cystic fibrosis; Index of individuality; Reference change value; Sweat chloride

Mesh:

Substances:

Year:  2017        PMID: 28739209      PMCID: PMC8179972          DOI: 10.1016/j.jcf.2017.07.008

Source DB:  PubMed          Journal:  J Cyst Fibros        ISSN: 1569-1993            Impact factor:   5.482


  16 in total

Review 1.  Inherent biological variation and reference values.

Authors:  Callum G Fraser
Journal:  Clin Chem Lab Med       Date:  2004       Impact factor: 3.694

2.  Biological variation: back to basics.

Authors:  Mario Plebani; Andrea Padoan; Giuseppe Lippi
Journal:  Clin Chem Lab Med       Date:  2015-02       Impact factor: 3.694

3.  Ivacaftor in subjects with cystic fibrosis who are homozygous for the F508del-CFTR mutation.

Authors:  Patrick A Flume; Theodore G Liou; Drucy S Borowitz; Haihong Li; Karl Yen; Claudia L Ordoñez; David E Geller
Journal:  Chest       Date:  2012-09       Impact factor: 9.410

4.  Variability of sweat chloride - A never ending story.

Authors:  Burkhard Tümmler
Journal:  J Cyst Fibros       Date:  2016-12-07       Impact factor: 5.482

5.  Biological Variation of Chloride and Sodium in Sweat Obtained by Pilocarpine Iontophoresis in Adults: How Sure are You About Sweat Test Results?

Authors:  Philippe Willems; Steven Weekx; Anissa Meskal; Sofie Schouwers
Journal:  Lung       Date:  2017-02-27       Impact factor: 2.584

6.  The predictive potential of the sweat chloride test in cystic fibrosis patients with the G551D mutation.

Authors:  Verena I Seliger; David Rodman; Fredrick Van Goor; Andreas Schmelz; Peter Mueller
Journal:  J Cyst Fibros       Date:  2013-04-28       Impact factor: 5.482

7.  Variability of sweat chloride concentration in subjects with cystic fibrosis and G551D mutations.

Authors:  F Vermeulen; C Le Camus; J C Davies; D Bilton; D Milenković; K De Boeck
Journal:  J Cyst Fibros       Date:  2016-03-17       Impact factor: 5.482

8.  Uncertainty of sweat chloride testing: does the right hand know what the left hand is doing?

Authors:  R J Mackay; C M Florkowski; P M George; C W Sies; S Woods
Journal:  Ann Clin Biochem       Date:  2008-11       Impact factor: 2.057

9.  A CFTR corrector (lumacaftor) and a CFTR potentiator (ivacaftor) for treatment of patients with cystic fibrosis who have a phe508del CFTR mutation: a phase 2 randomised controlled trial.

Authors:  Michael P Boyle; Scott C Bell; Michael W Konstan; Susanna A McColley; Steven M Rowe; Ernst Rietschel; Xiaohong Huang; David Waltz; Naimish R Patel; David Rodman
Journal:  Lancet Respir Med       Date:  2014-06-24       Impact factor: 30.700

10.  Sweat chloride as a biomarker of CFTR activity: proof of concept and ivacaftor clinical trial data.

Authors:  Frank J Accurso; Fredrick Van Goor; Jiuhong Zha; Anne J Stone; Qunming Dong; Claudia L Ordonez; Steven M Rowe; John Paul Clancy; Michael W Konstan; Heather E Hoch; Sonya L Heltshe; Bonnie W Ramsey; Preston W Campbell; Melissa A Ashlock
Journal:  J Cyst Fibros       Date:  2014-03       Impact factor: 5.527

View more
  7 in total

Review 1.  Accelerated Approval or Risk Reduction? How Response Biomarkers Advance Therapeutics through Clinical Trials in Cystic Fibrosis.

Authors:  N Mayer-Hamblett; D R VanDevanter
Journal:  Trends Mol Med       Date:  2020-08-28       Impact factor: 11.951

2.  Measuring the impact of CFTR modulation on sweat chloride in cystic fibrosis: Rationale and design of the CHEC-SC study.

Authors:  Edith T Zemanick; Michael W Konstan; Donald R VanDevanter; Steven M Rowe; J P Clancy; Katherine Odem-Davis; Michelle Skalland; Nicole Mayer-Hamblett
Journal:  J Cyst Fibros       Date:  2021-02-08       Impact factor: 5.482

3.  Out-of-clinic measurement of sweat chloride using a wearable sensor during low-intensity exercise.

Authors:  Dong-Hoon Choi; Grant B Kitchen; Mark T Jennings; Garry R Cutting; Peter C Searson
Journal:  NPJ Digit Med       Date:  2020-03-27

Review 4.  Regulation of CFTR Biogenesis by the Proteostatic Network and Pharmacological Modulators.

Authors:  Samuel Estabrooks; Jeffrey L Brodsky
Journal:  Int J Mol Sci       Date:  2020-01-10       Impact factor: 5.923

Review 5.  National Guidelines for the Performance of the Sweat Test in Diagnosis of Cystic Fibrosis on behalf of the Croatian Society of Medical Biochemistry and Laboratory Medicine and the Cystic Fibrosis Centre - Paediatrics and adults, University Hospital Centre Zagreb.

Authors:  Jasna Leniček Krleža; Merica Aralica; Duška Tješić-Drinković; Karolina Crneković; Jelena Culej; Gordana Fressl Juroš; Verica Horvat; Dara Metzner; Dijana Pamuković Jaram; Alma Pipić Kitter; Fran Smaić; Sanela Šimić Vojak; Livija Šimičević; Valentina Verić
Journal:  Biochem Med (Zagreb)       Date:  2022-02-15       Impact factor: 2.313

6.  Clinical Effectiveness of Lumacaftor/Ivacaftor in Patients with Cystic Fibrosis Homozygous for F508del-CFTR. A Clinical Trial.

Authors:  Scott D Sagel; Umer Khan; Sonya L Heltshe; John P Clancy; Drucy Borowitz; Daniel Gelfond; Scott H Donaldson; Antoinette Moran; Felix Ratjen; Jill M VanDalfsen; Steven M Rowe
Journal:  Ann Am Thorac Soc       Date:  2021-01

7.  Soft, skin-interfaced sweat stickers for cystic fibrosis diagnosis and management.

Authors:  Tyler R Ray; Maja Ivanovic; Paul M Curtis; Daniel Franklin; Kerem Guventurk; William J Jeang; Joseph Chafetz; Hannah Gaertner; Grace Young; Steve Rebollo; Jeffrey B Model; Stephen P Lee; John Ciraldo; Jonathan T Reeder; Aurélie Hourlier-Fargette; Amay J Bandodkar; Jungil Choi; Alexander J Aranyosi; Roozbeh Ghaffari; Susanna A McColley; Shannon Haymond; John A Rogers
Journal:  Sci Transl Med       Date:  2021-03-31       Impact factor: 17.956

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.